← Back to Search

Penile Traction Device

RestoreX Therapy for Erectile Dysfunction Post-Prostatectomy

N/A
Recruiting
Research Sponsored by Charitable Union for the Research and Education of Peyronie's Disease
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
>18 years old
Undergoing bilateral nerve-sparing prostatectomy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights

Study Summary

This trial will compare men who use the RestoreX device to preserve erectile function after prostatectomy to those who don't. The primary outcome will be changes in the IIEF-EFD scores between groups at 6 months.

Who is the study for?
Men over 18 with preserved erectile function facing prostatectomy can join this trial. They must be undergoing nerve-sparing surgery, not need post-op radiation or hormone therapy, and have had a stable sexual partner for the past 6 months. Men with severe ED or urethral complications from surgery are excluded.Check my eligibility
What is being tested?
The RestoreX penile traction device's effectiveness in maintaining erectile function after robotic-assisted prostatectomy is being tested. Participants will use the device for up to 9 months, with their erectile function scored at intervals to measure any changes.See study design
What are the potential side effects?
While specific side effects aren't listed here, penile traction devices may cause discomfort, bruising, or skin irritation. More serious side effects could include decreased sensation or injury to the penis if used improperly.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 years old.
Select...
I am having surgery to remove my prostate while preserving nerve function.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Erectile Function Post-Prostatectomy
Secondary outcome measures
Adverse events at 3 months
Adverse events at 6 months
Adverse events at 9 months
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment ArmExperimental Treatment2 Interventions
Men will begin utilizing PTT 30-60 minutes daily for 5-7 days weekly beginning 1 month post-prostatectomy until 6 months. After 6 months, they will have the option to continue to use the therapy for 3 additional months or discontinue at their discretion.
Group II: ControlActive Control1 Intervention
Men will not utilize PTT for the first 6 months post-prostatectomy. Beginning at 6 months, they may utilize PTT if they desire (open label) until 9 months post-prostatectomy.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Erectile Dysfunction (ED) include PDE5 inhibitors, vacuum erection devices, penile injections, and penile traction therapy. PDE5 inhibitors, such as sildenafil, work by increasing blood flow to the penis by inhibiting the enzyme phosphodiesterase type 5, which results in the relaxation of smooth muscle and vasodilation. Vacuum erection devices create a vacuum around the penis, drawing blood into the corpora cavernosa and maintaining the erection with a constriction ring. Penile injections involve injecting vasodilating agents directly into the penile tissue, which enhances blood flow and induces an erection. Penile traction therapy, like the RestoreX device, involves mechanical stretching of the penile tissue, which may help preserve or improve erectile function by promoting tissue health and preventing fibrosis. These treatments are crucial for ED patients as they offer various methods to achieve and maintain erections, thereby improving sexual function and quality of life.
Outcomes of RestoreX Penile Traction Therapy in Men With Peyronie's Disease: Results From Open Label and Follow-up Phases.Penile Rehabilitation Therapy Following Radical Prostatectomy: A Meta-Analysis.Penile rehabilitation should become the norm for radical prostatectomy patients.

Find a Location

Who is running the clinical trial?

Charitable Union for the Research and Education of Peyronie's DiseaseLead Sponsor
3 Previous Clinical Trials
180 Total Patients Enrolled

Media Library

RestoreX (Penile Traction Device) Clinical Trial Eligibility Overview. Trial Name: NCT05244486 — N/A
Erectile Dysfunction Research Study Groups: Treatment Arm, Control
Erectile Dysfunction Clinical Trial 2023: RestoreX Highlights & Side Effects. Trial Name: NCT05244486 — N/A
RestoreX (Penile Traction Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05244486 — N/A
Erectile Dysfunction Patient Testimony for trial: Trial Name: NCT05244486 — N/A
~20 spots leftby Sep 2024